Please check your internet connection and try again.
# Septran (Co-Trimoxazole / Trimethoprim-Sulfamethoxazole)
## Overview
Co-trimoxazole is a synergistic combination of a folate reductase inhibitor (trimethoprim) and a sulfonamide (sulfamethoxazole) in a typical 1:5 ratio. It exerts bactericidal activity by sequentially blocking two steps in bacterial folic acid biosynthesis.
## Primary Indications
* Urinary tract infections (UTI)
* *Pneumocystis jirovecii* pneumonia (PJP/PCP) treatment and prophylaxis
* Community-acquired MRSA skin and soft tissue infections
* Acute exacerbations of chronic bronchitis
* Traveler’s diarrhea (where locally susceptible)
## Adult Dosing
* **Mild/Moderate Bacterial Infection:** 960 mg (800 mg SMX/160 mg TMP) every 12 hours.
* **PCP Treatment:** 15–20 mg/kg/day (based on TMP component) divided every 6–8 hours for 21 days.
* **PCP Prophylaxis:** 960 mg daily or 3 times per week.
## Pediatric Dosing
* **General bacterial infections (≥2 months):** 8 mg/kg/day (TMP component) divided every 12 hours.
* **PCP Treatment:** 15–20 mg/kg/day (TMP component) divided every 6–8 hours.
* *Note:* Do not use in infants <2 months due to the risk of kernicterus.
## Dose Adjustments
* **Renal Impairment (CrCl):**
* CrCl 15–30 mL/min: Reduce dose by 50%.
* CrCl <15 mL/min: Not recommended unless hemodialysis is available.
* **Hepatic Impairment:** Use with caution; monitor for hepatotoxicity.
## Contraindications
* Known hypersensitivity to sulfonamides or trimethoprim.
* Documented megaloblastic anemia due to folate deficiency.
* Pregnancy at term (risk of kernicterus) and infants <2 months.
* Severe renal or hepatic insufficiency where monitoring is not possible.
* Concomitant use of dofetilide.
## Adverse Effects
* **Common:** Nausea, vomiting, skin rash, pruritus.
* **Serious:** Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), acute kidney injury (crystalluria), hyperkalemia (common with high doses), blood dyscrasias (agranulocytosis, thrombocytopenia), and *Clostridioides difficile*-associated diarrhea.
## Key Drug Interactions
* **Warfarin:** Significant potentiation of anticoagulant effect; monitor INR closely.
* **ACE Inhibitors/ARBs/Spironolactone:** Increased risk of hyperkalemia.
* **Methotrexate:** Increased risk of bone marrow suppression due to synergistic folate antagonism.
* **Phenytoin:** Inhibits metabolism, potentially increasing phenytoin levels.
## Monitoring
* **Baseline/Periodic:** Serum creatinine, electrolyte panel (specifically potassium), and CBC (for long-term use).
* **During therapy:** Monitor for signs of hypersensitivity (rash) and adequate hydration to prevent crystalluria.
## Clinical Pearls
* **Hydration:** Maintain adequate fluid intake to prevent sulfonamide crystal formation in urine.
* **Hyperkalemia:** Trimethoprim acts like a potassium-sparing diuretic (similar to amiloride); risk is higher in elderly patients or those on RAAS blockers.
* **Local Protocols:** Efficacy is highly dependent on local antibiogram patterns. Always consult institutional guidelines for empiric susceptibility.
* **Sulfa Allergy:** Cross-reactivity with other sulfonamides (e.g., sulfonylureas, thiazides) is debated, but caution is warranted in patients with severe historical anaphylaxis.
***
*Disclaimer: This information is for educational purposes and does not replace professional clinical judgment. Always verify current prescribing information, institutional protocols, and patient-specific factors via official drug monographs or clinical pharmacy resources before administering medication.*
